The proto-oncogene ErbB2 is known to be ampli®ed and to play an important role in the development of about one-third of human breast cancers. Phosphatidylinositol 3-kinase (PI3K), which is often activated in ErbB2-overexpressing breast cancer cells, is known to regulate cell proliferation and cell survival. Selective inhibitors of the PI3K pathway were used to assess the relevance of PI3K signaling in the anchorage-independent growth of a series of human mammary carcinoma cell lines. Wortmannin, LY294002, and rapamycin at concentrations that did not aect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70 S6K signi®-cantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression. A similar growth inhibition of ErbB2-overexpressing carcinoma lines was observed when a dominant negative p85 PI3K mutant was introduced into these cells. Forced expression of ErbB2 in breast cancer lines originally expressing low ErbB2 levels augmented receptor expression and sensitized those lines to LY294002-and rapamycin-mediated inhibition of colony formation. Furthermore, treatment with LY294002 resulted in the selective increase of cyclin-dependent kinase inhibitors p21
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Cip1 or p27 Kip1 and suppression of cyclin E-associated Cdk2 kinase activity in ErbB2-overexpressing lines, which may account for their hypersensitivity toward inhibitors of the PI3K pathway in anchorage-independent growth. Our results indicate that the PI3K/Akt/ p70 Introduction Ampli®cation and/or overexpression of the genes encoding the epidermal growth factor receptor (EGFR 2 ) or ErbB2 (Neu, HER2), two members of the ErbB family of receptor protein tyrosine kinases (RPTKs), occurs in 20 ± 30% of human breast cancers and is correlated with a high relapse rate and poor clinical prognosis (King et al., 1985; Slamon et al., 1987; Yokota et al., 1986) . Evidence to support a functional role for ErbB2 in cell transformation and mammary carcinogenesis came from studies demonstrating that overexpression of ErbB2 in NIH3T3 cells, human mammary epithelial cells, and transgenic mice leads to the constitutive activation of ErbB2 as well as the induction of cell transformation and mammary tumorigenesis (Di Fiore et al., 1987; Guy et al., 1992; Pierce et al., 1991) . Furthermore, the disruption of ErbB2 expression and function was shown to result in selective growth inhibition of the ErbB2-overexpressing mammary carcinoma cell lines (Colomer et al., 1994; Guy et al., 1992) , indicating the important role played by ErbB2 signaling in modulating cell proliferation in these cancers. Recent work has been aimed at determining a more detailed mechanism by which ErbB2 overexpression in breast cancer leads to enhancement of properties related to metastasis and resistance to chemotherapeutic agents, endocrine hormones, radiation, and cytokines Harari and Yarden, 2000) . Identi®cation of the precise roles played by mitogenic and anti-apoptotic signal transduction pathways in ErbB2-dependent mammary oncogenesis will lead to both a better understanding of the mechanisms underlying the biological behavior of those cancers and the potential development of eective methods to treat those cancers.
PI3K and mitogen activated protein kinase (MAPK) are regulators of two pathways that mediate proliferative signaling by activated RPTKs (Fruman et al., 1998; Robinson and Cobb, 1997) . Activation of PI3K and generation of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate in vivo are necessary for the activation of Akt/PKB and p70 S6K , downstream mediators of PI3K signaling, through phosphorylation of speci®c threonine and serine residues on these kinases (Downward, 1998) . Akt/PKB regulates cell survival by phosphorylating and inactivating the apoptotic mediators BAD (Datta et al., 1997) , caspase-9 (Cardone et al., 1998) , FKHRL1 (Brunet et al., 1999) , and IKK-a (Ozes et al., 1999; Romashkova and Makarov, 1999) and has been shown to be involved in regulating cell proliferation as well (Ahmed et al., 1997; Medema et al., 2000) . Control of cell growth by p70 S6K involves phosphorylation of the 40S ribosomal protein S6 that results in the up-regulated translation of speci®c mRNAs essential for cell growth and proliferation (Dufner and Thomas, 1999) . In mammalian cells, cyclinDCdk4, cyclinD-Cdk6, cylinE-Cdk2, and cyclinA-Cdk2 act sequentially in G 1 and S phases and are required for cell-cycle progression through this period. Cdk activity is tightly regulated by diverse mechanisms, including changes in the level of cyclins or Cdks, phosphorylation of positive and negative regulatory sites, and interaction with stoichiometric inhibitors including Cip/Kip and INK family of Cdk inhibitor proteins (Sherr and Roberts, 1999) .
Here, we investigated the role of PI3K-dependent signaling in the regulation of anchorage-independent growth in human mammary carcinoma cells. We found that soft agar colony formation of cell lines that overexpressed ErbB2 was much more severely inhibited by wortmannin (Arcaro and Wymann, 1993; Yano et al., 1993) and LY294002 (Vlahos et al., 1994) , two pharmacologically-unrelated speci®c inhibitors of PI3K, and by rapamycin Price et al., 1992) , an inhibitor of mammalian Target Of Rapamycin (mTOR), a potential downstream molecule of Akt, compared to that of tumor cell lines which express lower levels of ErbB2. Transfection of a dominant negative p85 PI3K mutant similarly resulted in growth inhibition of ErbB2-overexpressing cancer lines. Forced overexpression of ErbB2 in cell lines with low ErbB2 expression potentiated the growth inhibition of these lines in soft agar by LY294002 and rapamycin. Moreover, Cdk inhibitors were up-regulated and Cdk2 activity was down-regulated in ErbB2-overexpressing cell lines in response to treatment with LY294002. Together, our ®ndings suggest that breast cancer cell lines with ErbB2 overexpression possess an increased growth requirement for the PI3K/mTOR/ p70 S6K signaling pathway.
Results

PI3K inhibitors selectively inhibit the anchorage-independent growth of human breast cancer lines that overexpress ErbB2
Breast tumor cell lines that overexpress ErbB2 and ErbB3 have been demonstrated to possess ErbB2/ ErbB3 heterodimeric receptors that are constitutively phosphorylated and are associated with elevated PI3K activity (Alimandi et al., 1995; Kraus et al., 1987 Kraus et al., , 1993 . Therefore we investigated the role of PI3K signaling in a panel of human breast cancer cell lines, including those cell lines known to possess c-erbB2 gene ampli®cation and overexpression (Alimandi et al., 1995; Kraus et al., 1987) . To assess the importance of the PI3K pathway in anchorage-independent growth, we evaluated the eect of inhibitors of PI3K on colony growth in soft agar, a property of transformed and tumor cells which is closely correlated to tumorigenesis in vivo (Di Fiore et al., 1987; Pierce et al., 1991) . Wortmannin (Arcaro and Wymann, 1993; Yano et al., 1993) (250 nM), a well established and selective inhibitor of PI3K, did not reduce colony number by more than 8% nor the size distribution of ®ve tumor cell lines analysed (MCF-7, T-47D, MDA-MB-231, Hs578T, and ZR-75-1) relative to their untreated controls ( Figure 1a ,b, T-47D is shown as an example). In contrast, colony formation of three cell lines (SK-BR-3, BT-474 and MDA-MB-453) that are known to overexpress ErbB2 (Alimandi et al., 1995; Kraus et al., 1987) was suppressed 42 ± 57% by wortmannin relative to their respective controls ( Figure 1a ). Reductions in colony number were accompanied by reductions in colony size in those cell lines (Figure 1b , BT-474 is shown as an example).
In parallel experiments, we used LY294002 (Vlahos et al., 1994) , a structurally-unrelated inhibitor of PI3K, to establish that the inhibition of anchorage-independent growth was an eect speci®c to the inhibition of PI3K rather than to wortmannin. In the presence of LY294002 (10 mM), colony formation of each ErbB2-overexpressing cell line (SK-BR-3, BT-474, MDA-MB-361 and MDA-MB-453) was reduced by 52 ± 86% relative to controls (Figure 1c,d , SK-BR-3, MDA-MB-361 and MDA-MB-453 are shown). Interestingly, one cell line, ZR-75-1, which expresses a moderate level of ErbB2 (Figure 2a ), was also suppressed by LY294002 but was unaected by wortmannin under the conditions that we used. The colony forming abilities of the other nonoverexpressing cell lines were either unaected or only mildly (up to 25%) reduced (Figure 1c ,d, MCF-7 is shown). At concentrations greater or less than 10 mM, the degree of selective inhibition was less signi®cant, i.e. only 50% of those cell lines with high ErbB2 expression were growth-inhibited at 5 mM and over 50% of those cell lines with low ErbB2 expression were also growth-inhibited at 15 mM (data not shown), indicating a narrow eective concentration range for LY294002 in selectively growthinhibiting those tumor cell lines that overexpress ErbB2. The milder inhibition by wortmannin in comparison with LY294002 could be due to the fact that wortmannin has a relatively short half-life of about 8 h and was added only at the initial seeding of cells for the assay. Under similar conditions, neither wortmannin nor LY294002 caused a signi®cant inhibition of monolayer growth or apoptosis of normal breast epithelial lines AB589 and MCF-10F (data not shown), thus excluding the possibility of a general cytotoxic eect caused by these drugs.
As an alternative approach to inhibiting PI3K, we transiently-transfected these cell lines with an expression plasmid containing a dominant negative (dn) PI3K and control plasmids were transfected into SK-BR-3, BT-474, and MDA-MB-453 cells. Transfection eciency was determined to be at least 50%, as measured by GFP¯uorescence. Forty-eight hours after transfection, equivalent numbers of cells were seeded in semi-solid medium to assess colony formation. Photomicrographs depict the number and size of colonies in dominant negative p85 PI3K -transfected cultures compared to control cultures. To determine the expression of dominant negative p85 PI3K , whole cell lysates (20 mg) of transiently-transfected cells were analysed by immunoblotting with anti-p85 antibody. The mutant p85 protein co-migrates with endogenous p85 protein in SDS ± PAGE. IB, immunoblot mutant of the p85 subunit of PI3K or a control plasmid. Following transfection, Western blot analysis with anti-p85 antibody and colony assays were performed to assess the expression level of the mutant protein and the eect of dn p85 PI3K on anchorageindependent growth, respectively. Expression of dn p85 PI3K in the ErbB2-overexpressing lines SK-BR-3, BT-474, and MDA-MB-453 ranged between 2 ± 10-fold over endogenous p85 levels and in each cell line was associated with a signi®cant reduction in soft agar growth when compared to the respective empty vectortransfected cells (Figure 1e ). Transfection of cell lines with low ErbB2 levels, including MCF-7 and T-47D, did not result in appreciable levels of dn p85 PI3K as assessed by Western blot analysis (data not shown). This was attributed to a low transfection eciency, which was estimated to be less than 10% from parallel transfection experiments using a GFP expression plasmid (data not shown). Nevertheless, the sensitivity of ErbB2-overexpressing cancer lines to dn p85 PI3K in soft agar growth further supports the selective attenuation of growth that was observed using pharmacologic inhibitors of PI3K (Figure 1a ± d) . Together, these ®ndings indicate that, in anchorageindependent conditions, breast cancer cells overexpressing ErbB2 are more sensitive to PI3K inhibitors and thus may possess an increased requirement for PI3K compared to those cell lines that do not overexpress ErbB2.
Rapamycin-induced inhibition of anchorage-independent growth is correlated with ErbB2 expression level in breast cancer cell lines
To elucidate the PI3K downstream signaling components that are involved in mediating anchorage-independent growth, we investigated the eect of the immunosuppressant drug rapamycin Kuo et al., 1992; Price et al., 1992) , an inhibitor of the upstream activator of p70 S6K called mTOR (Dufner and Thomas, 1999) . Treatment with rapamycin (2 ng/ml) signi®cantly in- (Figure 1 ), the cell lines with low ErbB2 expression were not signi®cantly aected by rapamycin at this concentration ( Figure 2a ,b, MCF-7 is shown as an example). Therefore, it appears that overexpression of ErbB2 in breast cancer cell lines is correlated with their hypersensitivity to inhibitors of PI3K and rapamycin. Furthermore, with the exception of T-47D, the ErbB2 expression level is closely correlated with the level of Akt/PKB phosphorylation ( Figure 2a , bottom panels) con®rming previously reported data and suggesting activation of PI3K in these breast cancer cell lines. The expression of PTEN, a tumor suppressor and inhibitor of PI3K and Akt/PKB S6K and Akt/PKB phosphorylation in human breast cancer cells treated with LY294002 (in DMSO), rapamycin (in DMSO), or DMSO alone (untreated). Whole cell lysates were resolved by SDS ± PAGE and immunoblotted with anti-phospho-Akt (left) or anti-phospho-p70 S6K (right) antibody. Blots were stripped and re-probed with anti-Akt1 (Santa Cruz Biotechnology, Inc.), anti-p70 S6K (Santa Cruz Biotechnology, Inc.), and anti-actin (Sigma) antibodies to con®rm equivalent protein loading (not shown). IB, immunoblot. (c) Akt kinase activity following treatment with LY294002 in low and high ErbB2-expressing human breast cancer cell lines. Akt/PKB was precipitated with immobilized anti-Akt antibody and subjected to in vitro kinase assay using a GSK-3 fusion protein as substrate. Phosphorylation of substrate was detected by SDS ± PAGE and immunoblotting with a phospho-GSK-3 speci®c antibody. Parallel Coomassie blue staining of SDS gel and immunoblotting with anti-Akt antibody demonstrate equivalent protein in treated and untreated lanes. IB, immunoblot. (d) Erk1 and Erk2 phosphorylation in human breast cancer cells treated with wortmannin, LY294002, rapamycin, or DMSO as control. Whole cell lysates were resolved by SDS ± PAGE and immunoblotted with anti-phospho-ERK1/2 antibody. IB, immunoblot signaling (Stambolic et al., 1998) , was analysed in the same panel of breast cancer cells lines and was not found to vary signi®cantly among these cell lines (data not shown), suggesting that activation of a PI3K-dependent signaling pathway in ErbB2-overexpressing cells occurs downstream of PTEN.
To con®rm that the activities of PI3K and its downstream signaling components were eectively inhibited by the concentration of inhibitors used, the steady-state PI3K activity and activating phosphorylations of Akt/ PKB and p70 S6K were determined. Following the treatment of exponentially-growing monolayer cultures with 250 nM wortmannin, 10 mM LY294002, or 2 ng/ml rapamycin for 2 h, total cell extracts were examined for abundance of PI3K activity, and phosphorylation of Akt and p70 S6K . Treatment with wortmannin resulted in 40 ± 50% inhibition of total p85-associated PI3K activity (Figure 3a Our data indicate that treatment with PI3K inhibitors eectively suppressed PI3K activity and therefore downstream signaling, as re¯ected by attendant decreases in the phosphorylation of downstream molecules, i.e. Akt/ PKB and p70 S6K . We next directly assessed the kinase activity of Akt/PKB. Following treatment with LY294002 of low ErbB2-expressing (T-47D) and high ErbB2-expressing (SK-BR-3) breast cancer cell lines, an immobilized Akt/PKB antibody was used to pull down endogenous Akt/PKB, which was then subjected to an in vitro kinase assay with GSK-3 as a substrate. Immunoblotting with anti-phospho-GSK3 antibody demonstrated that treatment with LY294002 resulted in equivalent and substantial suppression of in vitro Akt/ PKB kinase activity in both tumor cell lines (Figure 3c ). Therefore, these data indicate that, under the conditions used, LY294002 is an eective inhibitor of both phosphorylation and activation of PI3K downstream components. Furthermore, treatment with wortmannin, LY294002, or rapamycin did not aect MAPK phosphorylation (Figure 3d) , arguing against the possibility that these drugs elicited a generalized cytotoxic eect. In addition, TUNEL assays performed to assess toxicity showed no signi®cant apoptosis in these cell lines (see Discussion). Collectively, our results suggest that the PI3K/Akt/mTOR/p70 S6K signaling pathway plays an important role in regulating cell proliferation in breast cancer cells that overexpress ErbB2.
Forced expression of ErbB2 in low ErbB2-expressing breast cancer cells sensitizes the cells to inhibition of colony formation by LY294002 and rapamycin
To further explore the contribution of ErbB2 overexpression to the sensitization of breast cancer cells to inhibitors of the PI3K pathway, we introduced an ErbB2 expression vector into low ErbB2-expressing cell lines that were not signi®cantly growth-inhibited by wortmannin, LY294002, or rapamycin (Figures 1 and 2 ). Sensitivity to these drugs was then determined by analysing their anchorage-independent growth relative to the respective control vector-transfected cells. Experiments were performed in a similar manner in MCF-7 (Figure 4 ) and MDA-MB-231 cells ( Figure 5 ). Several independent stable clones were selected and their levels of ErbB2 expression were compared to one-®fth of the MDA-MB-453 whole cell lysate by immunoblotting with anti-ErbB2 antibody. Four clones each of MCF-7 and MDA-MB-231 transfectants were selected for further analysis. They included the parental lines and clones with low or high ErbB2 expression (Figures 4a and 5a ). As expected, increased ErbB2 expression was correlated with increased ErbB2-associated PI3K activity (Figures  4b and 5b) . Whereas the parental MCF-7 and the two low ErbB2-expressing MCF-7 lines (clones 1 and 2) were refractory to either LY294002-or rapamycin-induced inhibition of colony formation, the high ErbB2-expressing line (clone 8) was inhibited by about 80% by each drug (Figure 4c) . A similar pattern of inhibition was observed in MDA-MB-231 clones. The high ErbB2-expressing cells, namely the pooled culture and clone 9, displayed a greater degree of anchorage-independent growth inhibition to LY294002 and rapamycin when compared to the low ErbB2-expressing lines, namely the parental line and clone 1 (Figure 5c ). However, the growth inhibition in these MDA-MB-231 clones was less dramatic than the inhibition observed in the high ErbB2-expressing MCF-7 clone, particularly with regard to the eect of rapamycin. These results further support the observation that ErbB2-overexpressing breast cancer lines with ampli®ed PI3K signaling possess an increased sensitivity to inhibitors of the PI3K signaling pathway in anchorage independent growth.
LY294002 selectively up-regulates Cdk inhibitors and inhibits cyclin E-associated Cdk2 activity in ErbB2-overexpressing breast cancer cells
To explore the underlying mechanism of the dierential eect of the PI3K inhibitor LY294002 on the growth of these breast cancer cell lines, we investigated the regulators of cell cycle progression, including Cdk2 activity, a critical regulator of the G 1 ? S transition (Sherr and Roberts, 1999) . Two low ErbB2-expressing lines MCF-7 and T-47D and two high ErbB2-expressing lines SK-BR-3 and BT-474 were chosen for this analysis. The expression and/or activity of various cyclins, Cdk inhibitors, and Cdks were examined and compared in control and drug-treated cells. After treatment with 10 mM LY294002 for 21 h, cyclin E-associated Cdk2 activity was more dramatically reduced in SK-BR-3 and BT-474 cells, more so in the latter cell line, than in MCF-7 and T-47D cells (Figure 6a , upper two panels). Cyclin E and Cdk2 protein levels remained unchanged in each cell line after drug treatment (Figure 6a , middle two panels). The expression level of Cdk inhibitors, including p21 Cip1 and p27 Kip1 , were also examined. There was no signi®cant change in the expression level of p21
Cip1 or p27 Kip1 in the two low ErbB2-expressing cancer cell lines after treatment with LY294002 ( Figure 6a , lower two panels). In contrast, while there was no change in the undetectable level of p27
Kip1 protein expression in SK-BR-3 cells, the amount of p21
Cip1 protein was signi®cantly increased following LY294002 treatment. Paradoxically, in BT-474 cells, the undetectable level of p21
Cip1 protein remained unchanged, but the level of p27
Kip1 protein was substantially augmented after LY294002 treatment (Figure 6a, lower two panels) . In addition, there was no signi®cant change in the expression level of cyclin D1, Cdk4, or Cdk6 in each cell line after drug treatment (data not shown). Figure 6b , upper panel, shows the quantitated Cdk2 activities of three independent experiments. The ratio of Cdk2 activity in drug-treated cells to that in control cells is shown in Figure 6b , lower panel. Since Cdk2 is essential for the G 1 ? S transition, our data suggest that inhibition of the PI3K signaling pathway by LY294002 causes a block at this point in the cell cycle in high ErbB2-expressing breast cancer cells but not in low ErbB2-expressing cells. 
Discussion
Our results indicate that those human breast cancer cells with overexpression and activation of ErbB2 (Slamon et al., 1987; Yokota et al., 1986) display an increased requirement for a signaling pathway mediated by PI3K and mTOR/p70 S6K in anchorageindependent growth. Additional evidence to support an increased role of PI3K signaling in ErbB2 breast tumors came from experiments which demonstrated that LY294002 eected a greater selective growth inhibition of a mammary tumor cell line derived from a transgenic MMTV-neu mouse compared to that of mammary tumor cell lines derived from MMTVheregulin or MMTV-v-Ha-ras transgenic mice (Amundadottir and Leder, 1998). The underlying mechanism of the increased sensitivity to PI3K and p70 S6K inhibitors in the anchorage-independent growth of ErbB2 overexpressing breast cancer cells is not clear. However, this phenomenon is likely to be related to the ampli®cation of ErbB2-mediated signaling such as the PI3K pathway since we were able to sensitize the low ErbB2-expressing breast cancer cells by forced expression of ErbB2 with an attendant increase in ErbB2-associated PI3K activity. It is also formally possible that the ErbB2-mediated ampli®cation of PI3K signaling results in down-regulation of other pathway(s) that have a function equivalent to the PI3K pathway and that are otherwise active and important for anchorageindependent growth. As a consequence, ErbB2-overexpressing cells develop a greater reliance on PI3K signaling in anchorage-independent growth. It will be interesting to see if activation of PI3K, Akt, or p70 S6K also leads to the sensitization of cells to inhibition of anchorage-independent growth by their respective inhibitors. However, our results do not exclude the possibility that ErbB2-mediated signaling pathways other than the PI3K pathway are equally important for the anchorage-independent growth of ErbB2-overexpressing breast cancer cells.
As a regulator of cell growth and proliferation (Dufner and Thomas, 1999) , p70 S6K may mediate a PI3K-dependent mitogenic signaling pathway essential to the progressive outgrowth of human breast tumors harboring ampli®cation and overexpression of the cerbB2 gene. This renders PI3K and its downstream signal transducers, such as p70 S6K , as potential targets for the treatment of these breast cancers. To explore this possibility, we examined the potential cytoxicity of PI3K inhibitors in human breast epithelial cell lines AB589 and MCF-10F, two cell lines originally isolated from non-malignant mammary tissue. While immunouorescence assays did not reveal signs of apoptosis in normal epithelial cells up to 48 h of exposure to wortmannin or LY294002, nuclear condensation and TUNEL-positive cells were evident in 4 ± 5% of SK-BR-3 cells (data not shown).
Our ®nding of the increased levels of p21 Cip1 or p27 Kip1 and decreased Cdk2 activity upon LY294002 treatment in ErbB2-overexpressing but not nonoverexpressing breast cancer cells could explain the enhanced sensitivity of the former to PI3K inhibitors. ErbB2-mediated down-regulation of p27 Kip1 (Yang et al., 2000) and up-regulation of p21 Cip1 (Yu et al., 1998) in breast cancer cells have been reported previously. The ErbB2-mediated decrease of p27
Kip1 was shown to be due to increased instability, which was dependent on the Grb2/MAPK pathway (Yang et al., 2000) . Forced expression of ErbB2 in the breast cancer line MDA-MB-435 was shown to render the cells resistant to taxol-induced apoptosis via increased levels of p21
Cip1 and its binding to p34Cdc2 (Yu et al., 1998) Cip1 in HER-2/neu-overexpressing cells (Zhou et al., 2001 ). This cytoplasmic localization was correlated with cell growth and proliferation, and inhibition of Akt/PKB was shown to result in localization of the protein to the nucleus and inhibition of cell growth, providing a mechanism by which the PI3K/Akt pathway can regulate cell proliferation (Zhou et al., 2001) . How PI3K/Akt signaling regulates p21 Cip1 protein levels is not known, though it may involve degradation or destabilization following its cytoplasmic localization by Akt/PKB. Our result of elevated p27 Kip1 in response to inhibition of PI3K signaling is in agreement with a report that treatment of human choroidal melanoma cells with LY294002 resulted in up-regulation of p27 Kip1 and G 1 growth arrest (Casagrande et al., 1998) . Our data also agree with the observation that inhibition of PI3K induces a senescence-like arrest in primary mouse embryo ®broblasts, which is mediated by increasing levels of p27
Kip1 (Collado et al., 2000) . The mechanism by which the PI3K pathway regulates p27
Kip1 levels may be forthcoming. Akt/PKB has been shown to phosphorylate and modulate the activity of certain transcription factors such as FKHRL1 (Brunet et al., 1999) . DAF-16, an orthologue of FKHRL1, was reported to regulate the cell cycle in C. elegans by activation of p27
Kip1 transcription . Thus, it is likely that the Akt-mediated PI3K pathway may regulate the expression of p21 Cip1 / p27
Kip1 through such a mechanism in breast cancer cells, though this hypothesis awaits formal testing. Interestingly, blockade of ErbB2 in BT-474 and SK-BR-3 cells by a monoclonal antibody was shown to lead to down-regulation of Cdk2 activity and G 1 arrest in these cells (Lane et al., 2000) . In addition, antisense-mediated inhibition of ErbB2 in high and low expressing breast cancer cell lines was shown to result in the selective growth inhibition of only high ErbB2-expressing breast cancer cell lines tested, i.e. BT-474 and SK-BR-3 (Roh et al., 2000) . Our results show that inhibition of PI3K signaling, a known downstream signaling pathway of ErbB2, produced a similar selective down-regulation of Cdk2 activity and growth inhibition, suggesting that interference of the PI3K pathway may underlie the eect of ErbB2 blockade observed by others. However, it still remains unclear as to why ErbB2-overexpressing breast cancer cells display a greater sensitivity to PI3K inhibitors relative to non-overexpressing cancer cells.
The minimal toxicity to non-malignant epithelial cells and the increased sensitivity of a speci®c subset of breast tumor cell lines to these drugs, particularly to rapamycin which is currently being evaluated in clinical trials as an immunosuppressive agent, raises the prospect of targeting the PI3K/mTOR/p70 S6K pathway to treat ErbB2 breast malignancies, which historically have been associated with a poor prognosis (Slamon et al., 1987) and are often refractory to conventional forms of chemotherapy (Houston et al., 1999) . Our data provide a molecular basis for the treatment of such cancers. Future in vivo ecacy studies in relevant animal tumor models will allow for further assessment of the therapeutic potential of pharmacologic agents directed against the PI3K/mTOR/p70 S6K signaling pathway in breast cancer.
Materials and methods
Cell culture
All cell lines were obtained originally from American Type Culture Collection except AB589. Human breast cancer cell lines MCF-7, T-47D, MDA-MB-231, ZR-75-1, Hs578T, SK-BR-3, BT-474, MDA-MB-361, MDA-MB-453 and nonmalignant mammary epithelial cell line AB589 were grown routinely at 378C with 5% CO 2 in complete growth medium (Dulbecco's modi®ed Eagle's medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Gibco), 5 mg/ml insulin (Sigma), penicillin (100 U/ml), streptomycin (50 mg/ml), and fungizone (2 mg/ml)). For drug treatment and analysis of PI3K signaling, monolayer cell cultures in exponential growth were detached with 0.05% Tryspin/ 0.5 mM EDTA and plated at subcon¯uent densities. Twenty-four hours after plating, cell cultures were incubated for 2 h in complete growth medium containing 250 nM wortmannin (Alexis), 10 mM LY294002 (Calbiochem), 2 ng/ ml rapamycin (Calbiochem), or 0.1% DMSO as untreated control.
Transfection
One microgram of pcDNA3HER2 (ErbB2 expression vector) was used to transfect MCF-7 and MDA-MB-231 cells using LIPOFECTAMINE TM 2000 according to the protocol provided by the manufacturer (LIFE Technologies). Transfected cells were selected for G418 resistance and single colonies were isolated, ampli®ed, and analysed for ErbB2 expression by immunoblotting with anti-ErbB2 antibody.
For transient transfection, cells were seeded at 80 ± 90% con¯uence on the day of transfection. Four micrograms of Dp85 plasmid or control plasmid were transfected into the cells using the LIPOFECTAMINE TM 2000 reagent according to the manufacturer's protocol. Forty-eight hours after transfection, cells were subjected to colony assay and protein analysis. In parallel experiments, equivalent amounts of pGFP plasmid were transfected into the cells. Cultures were observed by¯uorescence microscopy 24 to 48 h after transfection to assess transfection eciency, as determined by the percentage of cells displaying GFP uorescence. The Dp85 plasmid, which expresses a dominant negative mutant of PI3K, was obtained from Dr Julian Downward.
Colony assay
Subcon¯uent cultures in exponential growth were trypsinized, resuspended in complete growth medium, and made into single cell suspensions by passing through 27 gauge needles. The cell number in cell suspensions was determined by counting with a hemacytometer and cells were then plated in semi-solid medium composed of complete growth medium, 0.3% agar (Difco), and either 250 nM wortmannin, 10 mM LY294002, 2 ng/ml rapamycin, or 0.1% DMSO over a base composed of 0.7% agar in complete growth medium. Due to the intrinsic variability in the colony forming eciencies of the cell lines, each cell line was plated accordingly: T-47D 5 ). Cells were incubated at 378C with 5% CO 2 for 3 to 4 weeks, and complete growth medium (0.5 ml) without inhibitor was added every 3 ± 4 days. Colonies (40.1 mm) were counted from 10 random ®elds at 406magni®cation.
Immunoblotting and in vitro kinase assays
Cells were washed with Tris-Glu buer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM sodium phosphate, 0.1% glucose) and lysed on ice with cold RIPA buer (1% deoxycholate, 1% Triton X-100, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), 1% aprotinin, 1 mM phenylmethylsulfonyl¯uoride (PMSF), 1 mM sodium vanadate). Cell extracts were clari®ed by centrifugation at 12 000 r.p.m. and the protein concentrations of the supernatants were determined by Bradford assay. Levels of protein expression and phosphorylation were determined by separating RIPA-solubilized cell extracts (20 mg) by SDS ± PAGE and immunoblotting with antibodies speci®c for ErbB2 (c-Neu, Calbiochem), EGFR (Transduction Laboratories), p85 PI3K (Upstate Biotechnology, Inc.), Akt/PKB (New England Biolabs), phospho-Akt (Ser473, New England Biolabs), phospho-p70 S6K (Thr389, New England Biolabs), phospho-ERK1/2 (Thr202/Tyr204, New England Biolabs), cyclin E (Santa Cruz Biotechnology, Inc), Cdk 2 (Santa Cruz Biotechnology, Inc), p21
Cip1 (Santa Cruz Biotechnology, Inc), or p27
Kip1 (Santa Cruz Biotechnology, Inc). Bands were visualized by horseradish peroxidase-linked anti-mouse IgG or anti-rabbit IgG antibody (Transduction Laboratories) and ECL (Amersham).
For in vitro PI3K assays, cells were lysed with cold NP40 buer (1% NP-40, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% aprotinin, 1 mM PMSF, 1 mM sodium vanadate) and equivalent amounts of NP40-solubilized cell extracts (400 mg) were immunoprecipitated with anti-p85 PI3K (Upstate Biotechnology, Inc.) or anti-ErbB2 (c-Neu, Calbiochem) and protein A-sepharose beads (Repligen). Kinase assays were performed on immunoprecipitates as described previously (Liu et al., 1993) using [g-32 P]ATP and phosphatidylinositol (Avanti Polar Lipids) as substrates. Phosphorylated products were separated by thin layer chromatography, detected by autoradiography, and quantitated by densitometric scanning.
In vitro Akt kinase activity was assayed according to the protocol provided by the manufacturer (Cell Signaling). Brie¯y, cell lysates of control or LY294002-treated cells were immunoprecipitated with immobilized Akt antibody for 3 h at 48C and were subjected to in vitro kinase assay using a GSK-3 fusion protein as substrate. Phosphorylated GSK-3 fusion protein was detected by immunoblotting with a phospho-GSK-3a/b (Ser21/9) antibody (Cell Signaling).
For Cdk kinase assay, cells were lysed in a buer containing 50 mM HEPES, pH 7.4, 50 mM NaCl, 0.5% Triton X-100, 1 mM dithiothreitol (DTT), 20 mM NaF, 10 mM NaPPi, 400 mM PAO, 1 mM sodium vanadate, 1% aprotinin, and 5 mg/ml leupeptin (lysis buer). Two hundred micrograms of total cellular protein was immunoprecipitated with 2 ml of anti-cyclin E antibody (Santa Cruz Biotechnology, Inc) overnight at 48C followed by the addition of protein A-sepharose beads and further incubation for 1 h. Beads were collected and washed twice in lysis buer without protease and phosphatase inhibitors and once in kinase reaction buer (50 mM HEPES, pH 7.4, 10 mM MgCl 2 ). The washed beads were then resuspended in 40 ml of kinase reaction buer supplemented with 50 mM ATP, 1 mg Histone H1, 0.7 mCi [g-32 P]ATP and incubated for 20 min at 308C. The reaction was stopped by the addition of 66SDS loading buer and radiolabeled histone H1 was resolved by SDS ± PAGE, stained with Coomassie blue, and quantitated by autoradiography and densitometric scanning. Abbreviations EGFR, epidermal growth factor receptor; PI3K, phosphatidylinositol 3-kinase; RPTK, receptor protein tyrosine kinase; MAPK, mitogen activated protein kinase; PKB, protein kinase B; Cdk, cyclin-dependent kinase.
